Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
The Oncologist · 05.01.2024 · 29 (1) · 1-7
DOI: 10.1093/oncolo/oyad266 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Oncologist, online erschienen am 12.09.2023. Verfasst von Guillermo Villacampa und 3 weiteren Autor:innen. Beteiligte Einrichtung: SOLTI Breast Cancer Research Group, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Breast surgery in cases of de novo metastatic breast cancer (MBC) is associated with improved outcomes in retrospective studies, although the results of randomized controlled trials (RCTs) are conflicting. We aimed to investigate whether surgery in this context prolongs patient survival.
Methods
We performed a systematic review of the literature to identify RCTs comparing surgery of primary breast cancer to no surgery in patients with de novo MBC. Cochrane Library, Embase, Medline (OVID), and Web of Science were searched with latest update in July 2023, while conference proceedings were manually searched. Data concerning patient and tumor characteristics, as well as outcomes, were extracted. A meta-analysis with random effects models was performed considering heterogeneity between trials.
Results
Overall, 3255 entries were identified and 5 RCTs fulfilled all inclusion criteria, which had enrolled 1381 patients. The overall estimation in the intention-to-treat population showed no benefit for patients who had surgical excision of the primary breast tumor (HR = 0.93; 95% CI, 0.76-1.14). No subgroups in terms of receptor status or patterns of metastasis seemed to benefit from surgery, except for younger/premenopausal patients (HR = 0.74, 95% CI, 0.58-0.94). Breast surgery was associated with improved local progression-free survival (HR = 0.37, 95% CI, 0.19-0.74).
Conclusion
Surgery of the primary tumor in patients with de novo MBC does not prolong survival, except possibly in younger/premenopausal patients. Breast surgery should be offered within the context of well-designed clinical trials examining the issue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- SOLTI Breast Cancer Research Group, Spain.
- The Institute of Cancer Research, London, UK.
- Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
- Oncology/Pathology Department, Karolinska Institute, Stockholm, Sweden.
- Breast Center, Karolinska University Hospital and Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
ORCID-Profile: Irma Fredriksson, Alexios Matikas
Zitieren
APA
Villacampa, G., Papakonstantinou, A., Fredriksson, I., & Matikas, A. (2024). Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. The Oncologist, 29(1), 1-7. https://doi.org/10.1093/oncolo/oyad266
Vancouver
Villacampa G, Papakonstantinou A, Fredriksson I, Matikas A. Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. The Oncologist. 2024;29(1):1-7. doi:10.1093/oncolo/oyad266
BibTeX
@article{Villacampa2024,
author = {Villacampa, Guillermo and Papakonstantinou, Andri and Fredriksson, Irma and Matikas, Alexios},
title = {Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {1},
pages = {1--7},
doi = {10.1093/oncolo/oyad266}
}
EUVIMED